Author

Wei Xu

Observed name: W M Xu

Institutions: Qinghai Normal University, Lanzhou University

Observed institutions: Qingdao University, Anhui Medical University, Qinghai Normal University, Sichuan University, West China Hospital of Sichuan University, Taian City Central Hospital, Zhejiang Taizhou Hospital, Innovent Biologics (China), Lanzhou University

ORCID: 0009-0009-0310-7843

Observed ORCID: 0009-0009-0310-7843

OpenAlex ID: A5103934576

B7-H3: A promising therapeutic target for autoimmune diseases

2020 · Yuting Chen, Shi-Yang Guan, et al. · Cellular Immunology · 27

High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers

2025 · Peng Fan, Ziwei Qi, et al. · Cell Death and Disease · 16

Efficient Mamba: Overcoming the visual limitations of Mamba with innovative structures

2025 · Wei Xu, Yi Wan, et al. · Image and Vision Computing · 9

Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer

2024 · Zhenhua Liu, Ke Ma, et al. · BMJ Oncology · 8

Efficient global–local feature extraction via the Superior Efficient Transformer

2025 · Wei Xu, Yi Wan, et al. · Journal of Visual Communication and Image Representation · 4

Case Report: IgG4-RD-related ophthalmopathy combined with monoclonal gammopathy of undetermined significance

2025 · Shanshan Liang, Wei Xu, et al. · Frontiers in Immunology · 3

Fusion Attention Efficiently Integrating Channel and Spatial Attention for CNN Enhancement

2026 · Wei Xu, Zhonglin Ye, et al. · Lecture notes in electrical engineering

[Reevaluation of equivocal HER2 status detected by immunohistochemistry according to the 2019 guidelines for HER2 detection].

2020 · W M Xu, L N Zhang, et al. · PubMed

Works count: 8

Citation count: 67

H-index: 4

I10-index: 2